Two types of blood pressure drugs are now involved in the recall that began in late July over a suspected cancer-causing compound.
The recall of blood pressure medications continues and this time a new type of drug is involved.
In their latest announcement, Food and Drug Administration (FDA) officials said Solco Healthcare LLC has initiated a voluntary recall of one lot of Irbesartan and seven lots of Irbesartan HCTZ tablets.
The recall is due to the discovery of trace amounts of an unexpected impurity in a pharmaceutical ingredient known as N-nitrosodiethylamine (NDEA), which the FDA has classified as a “probable human carcinogen.”
Company officials said there have been no adverse effects reported from people taking these pills.
In late December, Aurobindo Pharma USA Inc. announced it is taking off store shelves 80 lots of its Amlodipine Valsartan, Valsartan HCTZ, and Valsartan tablets.
The company also said it hasn’t received any reports yet of adverse patient reactions to their products.
However, their tablets also contain the NDEA chemical.
The Aurobindo announcement involvement Valsartan and the Solco announcement involving Irbesartan are the latest in a series of recalls of medications designed to treat high blood pressure. The recall announcements began in late July.
Last month, officials at Mylan said the pharmaceutical company would recall all lots of its blood pressure medication valsartan.
The additional 104 lots were being taken off shelves “out of an abundance” of caution, company officials said, because of reports that valsartan products may contain traces of a potential cancer-causing impurity.
The previous week, Teva Pharmaceuticals announced they were voluntarily recalling two blood pressure medications due to an impurity that has been detected above “specification limits.”
The Teva products are Amlodipine/Valsartan combination tablets and Amlodipiine/Valsartan/Hydrochlorothiazide tablets.
Company officials urged people who use the tablets to continue taking the medication and consult with their doctor about potential alternative treatments. They said the potential harm of stopping their medication was higher than the potential risk from the tablets.
In late October, officials at the FDA announced they were adding a brand of drugs sold under the RemedyRepack to the list of medications recalled due to the ingredient in question.In late August, Accord Healthcare Inc. announced it was voluntarily recalling a specific lot of blood pressure medication after discovering a bottle had the wrong pills in it.The 100-pill bottle was supposed to have Hydrochlorothiazide Tablets USP 12.5 mg. Instead, it was filled with Spironolactone Tablets USP 25 mg. That medication is used to treat congestive heart failure and cirrhosis of the liver, among other ailments.